tiprankstipranks
FitLife Brands (FTLF)
NASDAQ:FTLF
US Market
Want to see FTLF full AI Analyst Report?

FitLife Brands (FTLF) AI Stock Analysis

40 Followers

Top Page

FTLF

FitLife Brands

(NASDAQ:FTLF)

Select Model
Select Model
Select Model
Neutral 60 (OpenAI - 5.2)
Rating:60Neutral
Price Target:
$9.50
▼(-33.24% Downside)
Action:ReiteratedDate:04/14/26
The score is primarily supported by solid financial fundamentals (growth and improved leverage) and a mixed-but-constructive strategic narrative around Irwin scaling and debt paydown. It is held back meaningfully by severe technical weakness (strong downtrend) and fundamental risk signals from margin compression, softer cash generation, and management’s decision to withhold 2026 guidance due to near-term uncertainty.
Positive Factors
Improving leverage and balance sheet
Material deleveraging over 2023–2025 and scheduled term/revolver paydowns meaningfully improve financial flexibility. Lower leverage reduces refinancing risk, supports capex/NPD and cross‑sell investments, and gives management time to execute margin fixes without immediate liquidity pressure.
Negative Factors
Material margin compression
Sharp margin declines reflect lower gross margins and mix shifts from higher‑margin online to lower‑margin wholesale/Irwin dynamics. Sustained margin pressure reduces operating leverage, constrains reinvestment capacity, and raises the bar for execution on supply‑chain and NPD initiatives to restore profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving leverage and balance sheet
Material deleveraging over 2023–2025 and scheduled term/revolver paydowns meaningfully improve financial flexibility. Lower leverage reduces refinancing risk, supports capex/NPD and cross‑sell investments, and gives management time to execute margin fixes without immediate liquidity pressure.
Read all positive factors

FitLife Brands (FTLF) vs. SPDR S&P 500 ETF (SPY)

FitLife Brands Business Overview & Revenue Model

Company Description
FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. It offers weight loss, general health, and sports nutrition supplements; precision sports nutrition formulations for pro...
How the Company Makes Money
FitLife Brands makes money primarily by selling nutritional supplements and related wellness products under its brand portfolio. Its core revenue stream is product sales, with a significant portion generated through direct-to-consumer channels (co...

FitLife Brands Earnings Call Summary

Earnings Call Date:Apr 01, 2026
(Q4-2025)
|
% Change Since: |
Next Earnings Date:May 20, 2026
Earnings Call Sentiment Neutral
The call was mixed: several material positives (Irwin acquisition and rapid online scaling, substantial Q4 revenue lift, contribution and adjusted EBITDA growth, and disciplined debt paydown) are tempered by clear ongoing weaknesses (legacy brand declines, MRC underperformance, margin compression from Irwin, inventory obsolescence, Amazon traffic headwinds, and protein input-cost pressures). Management outlined credible operational fixes (shelf-life extension, supply-chain hires, off-Amazon marketing, new product launches and cross-selling) but timing and magnitude of recovery remain uncertain, and management withheld 2026 guidance as a result.
Positive Updates
Irwin Acquisition and Early Scaling
Acquired Irwin Naturals on August 8, 2025; Irwin Q4 revenue $12.6M (89% wholesale), delivered ~6% organic growth in Q4 vs. 2024 when normalized for lost Costco/Rite Aid/CBD; Amazon ramp: Oct $60k, Nov $300k, Dec ~ $500k; online monthly run-rate grew from ~$0.5M at end of Q4 to ~$0.8M in Q1 2026 (implying $9M–$10M annualized); subscribers increased from ~500 to over 3,600.
Negative Updates
Legacy FitLife Q4 Revenue and Contribution Decline
Legacy FitLife Q4 revenue was $13.3M and fell 12% year-over-year (wholesale down 14%, online down 10%); contribution declined 18% to $4.3M and contribution margin fell to 32.5% from 34.9%.
Read all updates
Q4-2025 Updates
Negative
Irwin Acquisition and Early Scaling
Acquired Irwin Naturals on August 8, 2025; Irwin Q4 revenue $12.6M (89% wholesale), delivered ~6% organic growth in Q4 vs. 2024 when normalized for lost Costco/Rite Aid/CBD; Amazon ramp: Oct $60k, Nov $300k, Dec ~ $500k; online monthly run-rate grew from ~$0.5M at end of Q4 to ~$0.8M in Q1 2026 (implying $9M–$10M annualized); subscribers increased from ~500 to over 3,600.
Read all positive updates
Company Guidance
Management declined to give formal 2026 guidance because of first‑quarter weakness and uncertainty, but provided metric context: consolidated Q4 2025 revenue was $25.9M (+73% YoY) with wholesale $15.5M (60% of revenue, +213%) and online $10.5M (40%, +4%); adjusted gross margin excluding the Irwin inventory step‑up amortization was 37.0% (vs. 41.4% prior), contribution rose 47%, net income was $1.6M (vs. $2.1M) and adjusted EBITDA was $3.5M (+14%). For 2025, legacy FitLife (ex‑MRC/MusclePharm) grew organic revenue ~6% with online +16% and wholesale flat, MusclePharm grew ~5% while MRC declined ~15%; legacy FitLife Q4 revenue was $13.3M (68% online, 32% wholesale) and contribution fell 18% to $4.3M (32.5% of revenue). Irwin (acquired Aug 8, 2025) normalized revenue was $54M in both 2024 and 2025, Q4 Irwin revenue was $12.6M (89% wholesale), Q4 gross margin 28.0% (33.2% adjusted) and contribution 26.6% (31.8% adjusted); Irwin Amazon sales scaled from ~$60k (Oct) to ~$300k (Nov) to ~$500k (Dec) and are running ≈$0.8M/month in Q1 2026 (≈$9–10M annual run‑rate) with subscribers rising from ~500 to >3,600. Balance‑sheet actions include ~$1.9M term‑loan paydown in Q4 to a $44.7M balance, a ~$1.4M revolver reduction in Q1 and an additional ~$1.5M term payment, and management highlighted five priorities (supply‑chain fixes to eliminate ~$2M/year of obsolescence and potentially lift Irwin margins 300–400 bps, NPD, off‑Amazon demand generation, wholesale cross‑selling, and SG&A efficiency) before issuing formal guidance.

FitLife Brands Financial Statement Overview

Summary
Strong top-line momentum and improving leverage (debt-to-equity down to ~0.28 in 2025) support the profile, but 2025 showed sharp margin compression (net and EBITDA margins notably lower) and weaker operating/free cash flow versus 2024 despite good FCF-to-net-income conversion.
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
66
Positive
BreakdownMar 2026Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue81.46M64.47M52.70M28.80M27.91M
Gross Profit31.45M28.08M21.43M12.03M12.50M
EBITDA10.51M13.35M8.12M5.89M6.29M
Net Income6.33M8.98M5.30M4.43M5.41M
Balance Sheet
Total Assets106.32M58.53M55.35M25.71M21.51M
Cash, Cash Equivalents and Short-Term Investments1.65M4.47M1.14M13.28M9.90M
Total Debt45.25M13.46M20.15M103.00K158.00K
Total Liabilities62.68M22.41M28.31M4.32M4.16M
Stockholders Equity43.64M36.13M27.04M21.39M17.35M
Cash Flow
Free Cash Flow7.40M9.60M4.11M4.13M4.48M
Operating Cash Flow7.44M9.61M4.22M4.13M4.48M
Investing Cash Flow-42.54M-10.00K-35.99M0.00-529.00K
Financing Cash Flow32.09M-6.98M20.30M-750.00K-390.00K

FitLife Brands Technical Analysis

Technical Analysis Sentiment
Negative
Last Price14.23
Price Trends
50DMA
13.33
Negative
100DMA
14.99
Negative
200DMA
16.11
Negative
Market Momentum
MACD
-1.34
Positive
RSI
26.28
Positive
STOCH
22.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FTLF, the sentiment is Negative. The current price of 14.23 is above the 20-day moving average (MA) of 11.32, above the 50-day MA of 13.33, and below the 200-day MA of 16.11, indicating a bearish trend. The MACD of -1.34 indicates Positive momentum. The RSI at 26.28 is Positive, neither overbought nor oversold. The STOCH value of 22.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FTLF.

FitLife Brands Risk Analysis

FitLife Brands disclosed 13 risk factors in its most recent earnings report. FitLife Brands reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

FitLife Brands Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
61
Neutral
$1.65B5.80-36.19%0.89%-11.91%
61
Neutral
$473.23M19.9012.18%5.67%162.31%
60
Neutral
$86.96M23.1815.30%26.35%-30.60%
54
Neutral
$64.66M70.5424.97%2.81%-0.99%6.11%
53
Neutral
$345.51M33.562.03%8.28%-74.46%
44
Neutral
$58.48M-0.21-111.73%-9.47%-212.20%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FTLF
FitLife Brands
9.26
-6.11
-39.75%
HLF
Herbalife
15.98
9.35
141.03%
NATR
Nature's Sunshine Products
27.03
14.75
120.11%
HAIN
Hain Celestial
0.64
-2.28
-78.01%
USNA
USANA Health
18.72
-9.32
-33.24%
LFVN
LifeVantage
5.05
-6.39
-55.85%

FitLife Brands Corporate Events

Business Operations and StrategyFinancial Disclosures
FitLife Brands Highlights 2025 Results and Irwin Integration
Neutral
Apr 7, 2026
FitLife Brands reported its fourth-quarter and full-year 2025 performance on an April 1, 2026 earnings call, highlighting broad organic growth across most brand groupings except MRC and the first full-quarter contribution from Irwin Naturals, acqu...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
FitLife Brands Q4 2025 Results Highlight Irwin Acquisition
Neutral
Apr 1, 2026
FitLife Brands reported its fourth-quarter and full-year 2025 results on April 1, 2026, showing that the August 8 acquisition of Irwin Naturals drove a 73% year-on-year jump in quarterly revenue to $25.9 million and a 26% rise in annual revenue to...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 14, 2026